PMV Pharmaceuticals announced the latest results from a Phase 1/2 clinical trial of its potential first-in-class small molecule p53 reactivator rezatapopt (PC14586) for the treatment of patients with solid tumors. This candidate therapy is designed to selectively bind to the pocket of the TP53 Y220C mutant protein, thereby restoring wild-type or normal p53 protein structure and inhibiting tumor function. Previously, the US FDA granted PC14586 Fast Track designation for the treatment of patients with locally advanced or metastatic solid tumors carrying TP53 Y220C mutants.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.